Cystic fibrosis: An update for clinicians. Part 2: Hepatobiliary and pancreatic manifestations

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 12, 2014, Pages 1954-1962

  Ledder, Oren ^a   Haller, Wolfram ^a   Couper, Richard T L ^c   Lewindon, Peter ^d   Oliver, Mark ^a,b  

^a ROYAL CHILDREN'S HOSPITAL   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (United States)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Cirrhosis; Cystic fibrosis; Liver; Nutrition; Pancreas; Pancreatic enzymes

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ENZYME PRECURSOR; LIVER ENZYME; URSODEOXYCHOLIC ACID;

ALCOHOLIC FATTY LIVER; BILIARY CIRRHOSIS; CLINICAL FEATURE; CYSTIC FIBROSIS; DIABETES MELLITUS; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE COURSE; ELASTOGRAPHY; ENZYME REPLACEMENT; FOLLOW UP; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HEPATOBILIARY DISEASE; HEPATOMEGALY; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER INJURY; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MALABSORPTION; MORBIDITY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS DISEASE; PANCREAS EXOCRINE INSUFFICIENCY; PANCREAS TRANSPLANTATION; PANCREATITIS; PATHOGENESIS; PHOSPHOLIPID METABOLISM; PORTAL HYPERTENSION; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; SPLENOMEGALY; STEATORRHEA; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; BILIARY TRACT DISEASES; EXOCRINE PANCREATIC INSUFFICIENCY; LIVER DISEASES;

BILIARY TRACT DISEASES; CYSTIC FIBROSIS; DIABETES MELLITUS; EXOCRINE PANCREATIC INSUFFICIENCY; FOLLOW-UP STUDIES; HUMANS; LIVER DISEASES; PANCREATITIS;

EID: 84937434493     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12785     Document Type: Review

References (103)

1. Vawter GF, Shwachmann H. Cystic fibrosis in adults: an autopsy study. Pathol. Annu. 1979; 14: 357-382.
2. Bhardwaj S, Canlas K, Kahi C etal. Hepatobiliary abnormalities and disease in cystic fibrosis: epidemiology and outcomes through adulthood. J. Clin. Gastroenterol. 2009; 43: 858-864.
3. Cystic Fibrosis Foundation. Patient Registry 2003: Annual Report to the Centre Directors. Bethesda, MA: Cystic Fibrosis Foundation, 2004.
4. Debray D, Kelly D, Houwen R etal. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J. Cyst. Fibros. 2011; 10: S29-36.
5. Scott-Jupp R, Lama M, Tanner MS. Prevalence of liver disease in cystic fibrosis. Arch. Dis. Child. 1991; 66: 698-701.
6. Rowland M, Gallagher CG, O'Laoide R etal. Outcome in cystic fibrosis liver disease. Am. J. Gastroenterol. 2011; 106: 104-109.
7. Lewindon PJ, Shepherd RW, Walsh MJ etal. Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy. Hepatology 2011; 53: 193-201.
8. Feranchak AP, Sokol RJ. Cholangiocyte biology and cystic fibrosis liver disease. Semin. Liver Dis. 2001; 21: 471-488.
9. Nagel RA, Westaby D, Javaid A etal. Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet 1989; 2: 1422-1425.
10. Moyer K, Balistreri W. Hepatobiliary disease in patients with cystic fibrosis. Curr. Opin. Gastroenterol. 2009; 25: 272-278.
11. Freudenberg F, Broderick AL, Yu BB etal. Pathophysiological basis of liver disease in cystic fibrosis employing a DeltaF508 mouse model. Am. J. Physiol. Gastrointest. Liver Physiol. 2008; 294: G1411-1420.
12. Smith JL, Lewindon PJ, Hoskins AC etal. Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis. Hepatology 2004; 39: 1673-1682.
13. Ramm GA, Shepherd RW, Hoskins AC etal. Fibrogenesis in pediatric cholestatic liver disease: role of taurocholate and hepatocyte-derived monocyte chemotaxis protein-1 in hepatic stellate cell recruitment. Hepatology 2009; 49: 533-544.
14. Minagawa N, Nagata J, Shibao K etal. Cyclic AMP regulates bicarbonate secretion in cholangiocytes through release of ATP into bile. Gastroenterology 2007; 133: 1592-1602.
15. Woo K, Dutta AK, Patel V etal. Fluid flow induces mechanosensitive ATP release, calcium signalling and Cl transport in biliary epithelial cells through PKCzeta-dependent pathway. J. Physiol. 2008; 586: 2779-2798.
16. Bartlett JR, Friedman KJ, Ling SC etal. Genetic modifiers of liver disease in cystic fibrosis. JAMA 2009; 302: 1076-1083.
17. Colombo C, Apostolo MG, Ferrari M etal. Analysis of risk factors for the development of liver disease associated with cystic fibrosis. J. Pediatr. 1994; 124: 393-399.
18. Colombo C, Battezati PM, Crosignani A etal. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology 2002; 36: 1374-1382.
19. Witters P, Libbrecht L, Roskams T etal. Noncirrhotic presinusoidal portal hypertension is common in cystic fibrosis-associated liver disease. Hepatology 2011; 53: 1064-1065.
20. Maurage C, Lenaerts C, Weber A etal. Meconium ileus and its equivalent as a risk factor for the development of cirrhosis: an autopsy study in cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 1989; 9: 17-20.
21. Oppenheimer EH, Esterly JR. Hepatic changes in young infants with cystic fibrosis: possible relation to focal biliary cirrhosis. J. Pediatr. 1975; 86: 683-689.
22. Lewindon PJ, Pereira TN, Hoskins AC etal. The role of hepatic stellate cells and transforming growth factor-beta(1) in cystic fibrosis liver disease. Am. J. Pathol. 2002; 160: 1705-1715.
23. Pinto HC, Carniero de Moura M etal. Non-alcoholic steatohepatitis: from cell biology to clinical practice. J. Hepatol. 2006; 44: 197-208.
24. Lindblad A, Glaumann H, Strandvik B. Natural history of liver disease in cystic fibrosis. Hepatology 1999; 30: 1151-1158.
25. Sokol RJ, Durie PR. Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. J. Pediatr. Gastroenterol. Nutr. 1999; 28: S1-3.
26. Mueller-Abt PR, Frawley KJ, Greer RM etal. Comparison of ultrasound and biopsy findings in children with cystic fibrosis related liver disease. J. Cyst. Fibros. 2008; 7: 215-221.
27. Durieu I, Pellet O, Simonot L etal. Sclerosing cholangitis in adults with cystic fibrosis: a magnetic resonance cholangiographic prospective study. J. Hepatol. 1999; 30: 1052-1056.
28. Menten R, Leonard A, Clapuyt P etal. Transient elastography in patients with cystic fibrosis. Pediatr. Radiol. 2010; 40: 1231-1235.
29. Witters P, Lihbrecht L, Roskams T etal. Noncirrhotic presinusoidal portal hypertension is common in cystic fibrosis-associated liver disease. Hepatology 2011; 53: 1064-1065.
30. Lewindon PJ, Ramm GA. Cystic fibrosis-cirrhosis, portal hypertension, and liver biopsy: reply. Hepatology 2011; 53: 1065-1066.
31. Corbett K, Kelleher S, Rowland M etal. Cystic fibrosis-associated liver disease: a population-based study. J. Pediatr. 2004; 145: 327-332.
32. Brigman C, Feranchak A. Liver involvement in cystic fibrosis. Curr. Treat. Options Gastroenterol. 2006; 9: 484-496.
33. Colombo C, Battezzati PM, Podda M etal. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double blind multicentre trial. The Italian Group for the study of ursodeoxycholic acid in cystic fibrosis. Hepatology 1996; 23: 1484-1490.
34. Lindblad A, Glaumann H, Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 1998; 27: 166-174.
35. Cheng K, Ashby D, Smyth RL. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst. Rev. 2012; (10), CD000222.
36. Stalvey MS, Torrez DM, Hillan J etal. Growth hormone therapy improves growth in children with cystic fibrosis related liver disease. J. Pediatr. Endocrinol Metab. 2008; 21: 793-797.
37. Linnane B, Oliver MR, Robinson PJ. Does splenectomy in cystic fibrosis related liver disease improve lung function and nutritional status? A case series. Arch. Dis. Child. 2006; 91: 771-773.
38. Louis D, Duc ML, Reix P etal. Partial splenectomy for portal hypertension in cystic fibrosis related liver disease. Pediatr. Pulmonol. 2007; 42: 1173-1180.
39. Shah R, Mahour GH, Ford EG etal. Partial splenic embolization. An effective alternative to splenectomy for hypersplenism. Am. Surg. 1990; 56: 774-777.
40. Brandt CT, Rothbart LJ, Kumpe D etal. Splenic embolization in children: long term efficacy. J. Pediatr. Surg. 1989; 24: 642-645.
41. Aslanidou E, Fotoulaki M, Tsitouridis I etal. Partial splenic embolization: successful treatment of hypersplenism, secondary to biliary cirrhosis and portal hypertension in cystic fibrosis. J. Cyst. Fibros. 2007; 6: 212-214.
42. Nash KL, Collier JD, French J etal. Cystic fibrosis liver disease: to transplant or not to transplant? Am. J. Transplant. 2008; 8: 162-169.
43. Nightingale S, O'Loughlin EV, Dorney SFA etal. Isolated liver transplantation in children with cystic fibrosis-an Australian experience. Pediatr. Transplant. 2010; 14: 779-785.
44. Gridelli B. Liver: benefit of liver transplantation in patients with cystic fibrosis. Nat. Rev. Gastroenterol. Hepatol. 2011; 8: 187-188.
45. Mendizabal M, Reddy KR, Cassuto J etal. Liver transplantation in patients with cystic fibrosis: analysis of United Network for Organ Sharing data. Liver Transpl. 2011; 17: 243-250.
46. Nash EF, Volling C, Gutierrez CA etal. Outcomes of patients with cystic fibrosis undergoing lung transplantation with and without cystic fibrosis-associated liver cirrhosis. Clin. Transplant. 2012; 26: 34-41.
47. Bandsma RHJ, Bozic MA, Fridell JA etal. Simultaneous liver-pancreas transplantation for cystic fibrosis-related liver disease: a multicentre experience. J. Cyst. Fibros. 2014; 13: 471-477. Available from URL: http://dx.doi.org/10.1016/j.jcf.2013.12.010.
48. Kopelman H, Durie P, Gaskin K etal. Pancreatic fluid secretion and protein hypersecretion in cystic fibrosis. N. Engl. J. Med. 1985; 312: 329-334.
49. Ooi CY, Dorfman R, Cipolli M etal. Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology 2011; 140: 153-161.
50. Szeifert GT, Szabo M, Papp Z. Morphology of cystic fibrosis at 17 weeks of gestation. Clin. Genet. 1985; 28: 556-561.
51. Meyerholz DK, Stoltz DA, Pezzulo AA etal. Pathology of gastrointestinal organs in a porcine model of cystic fibrosis. Am. J. Pathol. 2010; 176: 1377-1389.
52. Sturgess JM. Structural and developmental abnormalities of the exocrine pancreas in cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 1984; 3: S55-S66.
53. Durie PR, Forstner GG. Pathophysiology of the exocrine pancreas in cystic fibrosis. J. R. Soc. Med. 1989; 82 (Suppl. 16): 2-10.
54. Sequeiros IM, Hester K, Callaway M etal. MRI appearance of the pancreas in patients with cystic fibrosis: a comparison of pancreas volume in diabetic and non-diabetic patients. Br. J. Radiol. 2010; 83: 921-926.
55. Kristidis P, Bozon D, Corey M etal. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am. J. Hum. Genet. 1992; 50: 1178-1184.
56. Ahmed N, Corey M, Forstner G etal. Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. Gut 2003; 52: 1159-1164.
57. Centre for Disease Control and Prevention. Cystic fibrosis: clinical validity. Office of Public Health Genomics; 2007.
58. Waters DL, Dorney SFA, Gaskin KJ etal. Pancreatic function in infants identified as having cystic fibrosis in a neonatal screening program. N. Engl. J. Med. 1990; 322: 303-308.
59. Wilschanski M, Zielenski J, Markiewicz D etal. Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. J. Pediatr. 1995; 127: 705-710.
60. Cipolli M, Castellani C, Wilcken B etal. Pancreatic phenotype in cystic fibrosis patients identified by mutation screening. Arch. Dis. Child. 2007; 92: 842-846.
61. Gaskin KJ, Durie PR, Lee L etal. Colipase and lipase secretion in childhood-onset pancreatic insufficiency. Gastroenterology 1984; 86: 1-7.
62. Carriere F, Laugier R, Barrowman JA etal. Gastric and pancreatic lipase levels during a test meal in dogs. Scand. J. Gastroenterol. 1993; 28: 443-454.
63. Layer P, Go VL, DiMagno EP. Fate of pancreatic enzymes during small intestinal aboral transit in humans. Am. J. Physiol. 1986; 251: G475-480.
64. Pencharz PB, Durie PR. Pathogenesis of malnutrition in cystic fibrosis, and its treatment. Clin. Nutr. 2000; 19: 387-394.
65. Keller J, Aghdassi AA, Lerch MM etal. Tests of pancreatic exocrine function -clinical significance in pancreatic and non-pancreatic disorders. Best Pract. Res. Clin. Gastroentrerol. 2009; 23: 425-439.
66. Corey M, McLaughlin FJ, Williams M etal. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J. Clin. Epidemiol. 1988; 41: 583-591.
67. Durie PR, Newth CJ, Forstner GG etal. Malabsorption of medium-chain triglycerides in infants with cystic fibrosis: correction with pancreatic enzyme supplement. J. Pediatr. 1980; 96: 862-864.
68. Loser C, Mollgaard A, Folsch UR. Faecal elastase 1: a novel, highly sensitive and specific tubeless pancreatic function test. Gut 1996; 39: 580-586.
69. Seigmund E, Lohr JM, Schuff-Werner P. The diagnostic validity of non-invasive pancreatic function tests-a meta-analysis. Z. Gastroenterol. 2004; 42: 1117-1128.
70. Weintraub A, Blau H, Mussaffi H etal. Exocrine pancreatic function testing in patients with cystic fibrosis and pancreatic sufficiency: a correlation study. J. Pediatr. Gastroenterol. Nutr. 2009; 48: 306-310.
71. Toouli J, Biankin AV, Oliver MR etal. Management of pancreatic exocrine insufficiency: Australasian Pancreatic Club recommendations. Med. J. Aust. 2010; 193: 461-467.
72. Walkowiak J, Nousia-Arvanitakis S, Agguridaki C etal. Longitudinal follow-up of exocrine pancreatic function in pancreatic sufficient cystic fibrosis patients using the fecal elastase-1 test. J. Pediatr. Gastroenterol. Nutr. 2003; 36: 474-478.
73. Caras S, Boyd D, Zipfel L etal. Evaluation of stool collections compared to measure the efficacy of pancreatic enzyme replacement therapy in subjects with exocrine pancreatic insufficiency. J Pediatr. Gastroenterol. Nutr. 2011; 53: 634-640.
74. Watkins JB, Klein PD, Schoeller DA etal. Diagnosis and differentiation of fat malabsorption in children using 13C-labeled lipids: trioctanoin, triolein and palmitic acid. Gastroenterology 1982; 82: 911-917.
75. Dorsey J, Buckley DM, Summer S etal. Fat malabsorption in cystic fibrosis: comparison of quantitative fat assay and a novel assay using fecal lauric/behenic acid. J. Pediatr. Gastroenterol. Nutr. 2010; 50: 441-446.
76. Anthony H, Collins CE, Davidson G etal. Pancreatic enzyme replacement therapy in cystic fibrosis: Australian guidelines. Pediatric gastroenterological society and the dietitians association of Australia. J. Paediatr. Child Health 1999; 35: 125-129.
77. Schwarzenberg SJ, Wielinski CL, Shamieh I etal. Cystic fibrosis-associated colitis and fibrosing colonopathy. J. Pediatr. 1995; 127: 565-570.
78. DiMagno EP. Gastric acid suppression and treatment of severe exocrine pancreatic insufficiency. Best Pract. Res. Clin. Gastroenterol. 2001; 15: 477-486.
79. Colombo C, Fredella C, Russo MC etal. Efficacy and tolerability of Creon for Children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single arm, multicenter study. Pancreas 2009; 38: 693-699.
80. Borowitz D, Stevens C, Brettman LR etal. International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients. J. Cyst. Fibros. 2011; 10: 443-452.
81. Smyth RL, Ashby D, O'Hea U etal. Fibrosing colonopathy in cystic fibrosis: results of a case-control study. Lancet 1995; 346: 1247-1251.
82. Baker SS. Delayed release pancrelipase for the treatment of pancreatic exocrine insufficiency associated with cystic fibrosis. Ther. Clin. Risk Manag. 2008; 4: 1079-1084.
83. Ng SM, Jones AP. Drug therapies for reducing gastric acidity in people with cystic fibrosis. Cochrane Database Syst. Rev. 2012; 4: CD003424.
84. Aldamiz-Echevarria L, Prieto JA, Andrade F etal. Persistence of essential fatty acid deficiency in cystic fibrosis despite nutritional therapy. Pediatr. Res. 2009; 66: 585-589.
85. Wouthuyzen-Bakker M, Bodewes FA, Verkade HJ. Persistent fat malabsorption in cystic fibrosis; lessons from patients and mice. J. Cyst. Fibros. 2011; 10: 150-158.
86. Oliver C, Jahnke N. Omega-3 fatty acids for cystic fibrosis. Cochrane Database Syst. Rev. 2011.(8), CD002201.
87. Sagel SD, Sontag MK, Anthony MM etal. Effect of an antioxidant rich multivitamin supplement in cystic fibrosis. J. Cyst. Fibros. 2011; 10: 31-36.
88. Hollander FM, de Roos NM, Dopheide J etal. Self-reported use of vitamins and other nutritional supplements in adult patients with cystic fibrosis. Is daily practice in concordance with recommendation? Int. J. Vitam. Nutr. Res. 2010; 80: 408-415.
89. Augarten A, Ben Tov A, Madgar I etal. The changing face of the exocrine pancreas in cystic fibrosis: the correlation between pancreatic status, pancreatitis and cystic fibrosis genotype. Eur. J. Gastroenterol. Hepatol. 2008; 20: 164-168.
90. Solomon S, Whitcomb DC. Genetics of pancreatitis: an update for clinicians and genetic counsellors. Curr. Gastroenterol. Rep. 2012; 14: 112-117.
91. Bishop MD, Freedman SD, Zielenski J etal. The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis. Hum. Genet. 2005; 118: 372-381.
92. Lucidi V, Alghisi F, Dall'Oglio L etal. The etiology of acute recurrent pancreatitis in children: a challenge for paediatricians. Pancreas 2011; 40: 517-521.
93. De Cid R, Ramos MD, Aparisi L etal. Independent contribution of common CFTR variants to chronic pancreatitis. Pancreas 2010; 39: 209-215.
94. Nathan B, Moran A. Treatment recommendations for cystic fibrosis-related diabetes: too little, too late? Thorax 2011; 66: 555-556.
95. Rana M, Munns CF, Selvadurai HC etal. Increased detection of cystic fibrosis related diabetes in Australia. Arch. Dis. Child. 2011; 96: 823-826.
96. Baker EH, Wood DM, Brennan AL etal. Hyperglycemia and pulmonary infection. Proc. Nutr. Soc. 2006; 65: 227-235.
97. Moran A, Dunitz J, Nathan B etal. Cystic fibrosis related diabetes: current trends in prevalence, incidence and mortality. Diabetes Care 2009; 32: 1626-1631.
98. Milla CE, Warwick WJ, Moran AM. Trends in pulmonary function in cystic fibrosis patients correlate with the results of oral glucose tolerance test at baseline. Am. J. Respir. Crit. Care Med. 2001; 162: 891-895.
99. Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC etal. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010; 33: 2697-2708.
100. Socorro Rayas M, Willey-Courand DB, Lockwood Lynch J etal. Improved screening for cystic fibrosis-related diabetes by an integrated care team using an algorithm. Pediatr. Pulmonol. 2014; 49: 971-977.
101. Noronhaa RM, Damacenob N, Muramatub LH etal. Importance of screening with oral glucose tolerance test for early diagnosis of cystic fibrosis-related diabetes mellitus. Pediatr. Diabetes 2014; 15: 309-312.
102. Hameed S, Jaffe A, Verge CF. Cystic fibrosis related diabetes (CFRD-the end stage of progressive insulin deficiency. Pediatr. Pulmonol. 2011; 46: 747-760.
103. Kolouskova S, Zemkova D, Bartosova J etal. Low-dose insulin therapy in patients with cystic fibrosis and early-stage insulinopenia prevents deterioration of lung function: a 3 year prospective study. J. Pediatr. Endocrinol. Metab. 2011; 24: 449-454.